Search Results 1731-1740 of 19441 for hemoglobin

1. Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   * Hemoglobin ≥ 8.0 g/dL (obtained ≤ 14 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 14 days prior to ...

2. Elotuzumab In Immunoglobulin G4-Related Disease (IgG4-RD) - Mayo Clinic

   Hemoglobin < 10 g/dL;; Platelet count < 75 x 10^9/L;; Estimated glomerular filtration rate (eGFR) ≤ 45 ml/minute/1.73m^2. The use of supplemental oxygen at ...

3. Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis - Mayo Clinic

   Subjects with hemoglobin ≥ 10 g/dL. 9. Subjects with total bilirubin < 2× ULN. 10. Men and women of child-bearing potential (WOCBP) must agree to practice ...

4. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   - Hemoglobin >= 9 g/dL or >= 5.6 mmol/L(within 14 days of registration) - Criteria must be met without packed red blood cell (pRBC) transfusion within the ...

5. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL (uncorrected by RBC transfusion); Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100 × 109/L. Have adequate coagulation ...

6. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

   Hemoglobin >= 8 g/dL, within 2 weeks of randomization. Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known ...

7. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   Total hemoglobin ≥ 8 g/dL;; Patients who do not meet criteria for hematologic function because of MM-related cytopenias (e.g., due to extensive marrow ...

8. A Study of Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery - Mayo Clinic

   Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion (within 2 weeks of patient registration [for blood results] and 30 days of ...

9. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

   Hemoglobin ≥ 9 g/dL with or without transfusions;; Platelets ≥ 100 × 10^9 /L;; AST and ALT ≤ 2.5 × ULN; in patients with liver metastases ≤ 5 × ULN;; Total ...

10. A Study to Evaluate the Effectiveness and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects with Mycosis Fungoides - Mayo Clinic

    Clinically significant anemia (hemoglobin < 8 g/dL), neutropenia (absolute neutrophil count [ANC] < 1000/mm3) or thrombocytopenia (platelets < 50,000/mm^3) at ...